Page 1702 - Williams Hematology ( PDFDrive )

1676 Part XI: Malignant Lymphoid Diseases Chapter 102: Burkitt Lymphoma 1677

32. Donati D, Zhang LP, Chêne A, et al: Identification of a polyclonal B-cell activator in 52. Hummel M, Reiter S, Adam K, et al: Effective treatment and prophylaxis of hyperuri-
Plasmodium falciparum. Infect Immun 72:5412–5418, 2004. cemia and impaired renal function in tumor lysis syndrome with low doses of rasburi-
33. Chêne A, Donati D, Guerreiro-Cacais AO, et al: A molecular link between malaria and case. Eur J Haematol 80:331–336, 2008.
Epstein-Barr virus reactivation. PLoS Pathog 3:e80, 2007. 53. Choi KA, Lee JE, Kim YG, et al: Efficacy of continuous venovenous hemofiltration with
34. Zauner L, Melroe GT, Sigrist JA, et al: TLR9 triggering in Burkitt’s lymphoma cell chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor
lines suppresses the EBV BZLF1 transcription via histone modification. Oncogene 29: lysis syndrome. Ann Hematol 88:639–645, 2009.
4588–4598, 2010. 54. Saccente SL, Kohaut EC, Berkow RL: Prevention of tumor lysis syndrome using contin-
35. Chattopadhyay PK, Chelimo K, Embury PB, et al: Holoendemic malaria exposure is uous veno-venous hemofiltration. Pediatr Nephrol 9:569–573, 1995.
associated with altered Epstein-Barr virus-specific CD8(+) T-cell differentiation. J Virol 55. Lacasce A, Howard O, Lib S, et al: Modified magrath regimens for adults with
87:1779–1788, 2013. Burkitt and Burkitt-like lymphomas: Preserved efficacy with decreased toxicity. Leuk
36. Torgbor C, Awuah P, Deitsch K, et al: A multifactorial role for P. falciparum malaria in Lymphoma 45:761–767, 2004.
endemic Burkitt’s lymphoma pathogenesis. PLoS Pathog 10:e1004170, 2014. 56. Mead GM, Sydes MR, Walewski J, et al: An international evaluation of CODOX-M
37. Yano T, van Krieken JH, Magrath IT, et al: Histogenetic correlations between subcate- and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: Results of United
gories of small noncleaved cell lymphomas. Blood 79:1282–1290, 1992. Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264–1274, 2002.
38. Brady G, MacArthur GJ, Farrell PJ: Epstein-Barr virus and Burkitt lymphoma. J Clin 57. Mead GM, Barrans SL, Qian W, et al: A prospective clinicopathologic study of dose-
Pathol 60:1397–1402, 2007. modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using
39. Lundin C, Hjorth L, Behrendtz M, et al: Submicroscopic genomic imbalances in cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 112:
Burkitt lymphomas/leukemias: Association with age and further evidence that 8q24/ 2248–2260, 2008.
MYC translocations are not sufficient for leukemogenesis. Genes Chromosomes Cancer 58. Barnes JA, Lacasce AS, Feng Y, et al: Evaluation of the addition of rituximab to
52:370–377, 2013. CODOX-M/IVAC for Burkitt’s lymphoma: A retrospective analysis. Ann Oncol 22:1859–1864,
40. Scholtysik R, Kreuz M, Klapper W, et al: Detection of genomic aberrations in molec- 2011.
ularly defined Burkitt’s lymphoma by array-based, high resolution, single nucleotide 59. Corazzelli G, Frigeri F, Russo F, et al: RD-CODOX-M/IVAC with rituximab and intra-
polymorphism analysis. Haematologica 95:2047–2055, 2010. thecal liposomal cytarabine in adult Burkitt lymphoma and “unclassifiable” highly
41. Bellan C, Stefano L, Giulia de F, et al: Burkitt lymphoma versus diffuse large B-cell aggressive B-cell lymphoma. Br J Haematol 156:234–244, 2012.
lymphoma: A practical approach. Hematol Oncol 28:53–56, 2010. 60. Evens AM, Carson KR, Kolesar J, et al: A multicenter phase II study incorporating
42. Jaffe ES, Pittaluga S: Aggressive B-cell lymphomas: A review of new and old entities high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen
in the WHO classification. Hematology Am Soc Hematol Educ Program 2011:506–514, for untreated Burkitt’s lymphoma. Ann Oncol 24:3076–3081, 2013.
2011. 61. Dunleavy K, Pittaluga S, Shovlin M, et al: Low-intensity therapy in adults with Burkitt’s
43. Lindsley RC, LaCasce AS: Biology of double-hit B-cell lymphomas. Curr Opin Hematol lymphoma. N Engl J Med 369:1915–1925, 2013.
19:299–304, 2012. 62. Thomas DA, Cortes J, O’Brien S, et al: Hyper-CVAD program in Burkitt’s-type adult
44. Green TM, Young KH, Visco C, et al: Immunohistochemical double-hit score is a acute lymphoblastic leukemia. J Clin Oncol 17:2461–2470, 1999.
strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with 63. Fayad L, Thomas D, Romaguera J: Update of the M. D. Anderson Cancer Center experi-
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol ence with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type
30:3460–3467, 2012. lymphomas. Clin Lymphoma Myeloma 8 (Suppl 2):S57–S62, 2007.
45. Magrath I, Adde M, Shad A, et al: Adults and children with small non-cleaved-cell 64. Thomas DA, Faderl S, O’Brien S, et al: Chemoimmunotherapy with hyper-CVAD plus
lymphoma have a similar excellent outcome when treated with the same chemotherapy rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lym-
regimen. J Clin Oncol 14:925–934, 1996. phoblastic leukemia. Cancer 106:1569–1580, 2006.
46. Rizzieri DA, Johnson JL, Niedzwiecki D, et al: Intensive chemotherapy with and with- 65. Rizzieri DA, Johnson JL, Byrd JC, et al: Alliance for Clinical Trials In Oncology
out cranial radiation for Burkitt leukemia and lymphoma: Final results of Cancer and (ACTION): Improved efficacy using rituximab and brief duration, high intensity che-
Leukemia Group B Study 9251. Cancer 100:1438–1448, 2004. motherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and
47. Soussain C, Patte C, Ostronoff M, et al: Small noncleaved cell lymphoma and leukemia Leukemia Group B study 10 002. Br J Haematol 165:102–111, 2014.
in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. 66. Song KW, Barnett MJ, Gascoyne RD, et al: Haematopoietic stem cell transplantation as pri-
Blood 85:664–674, 1995. mary therapy of sporadic adult Burkitt lymphoma. Br J Haematol 133:634–637, 2006.
48. Link MP, Donaldson SS, Berard CW, et al: Results of treatment of childhood localized 67. Hoffmann C, Wolf E, Wyen C, et al: AIDS-associated Burkitt or Burkitt-like lymphoma:
non-Hodgkin’s lymphoma with combination chemotherapy with or without radiotherapy. Short intensive polychemotherapy is feasible and effective. Leuk Lymphoma 47:1872–
N Engl J Med 322:1169–1174, 1990. 1880, 2006.
49. Magrath IT, Haddy TB, Adde MA: Treatment of patients with high grade non-Hodgkin’s 68. Kelly JL, Toothaker SR, Ciminello L, et al: Outcomes of patients with Burkitt lymphoma
lymphomas and central nervous system involvement: Is radiation an essential compo- older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma
nent of therapy? Leuk Lymphoma 21:99–105, 1996. Myeloma 9:307–310, 2009.
50. Hsu HH, Chan YL, Huang CC: Acute spontaneous tumor lysis presenting with hype- 69. Grigg AP, Seymour JF: Graft versus Burkitt’s lymphoma effect after allogeneic marrow
ruricemic acute renal failure: Clinical features and therapeutic approach. J Nephrol transplantation. Leuk Lymphoma 43:889–892, 2002.
17:50–56, 2004. 70. Perkins AS, Friedberg JW: Burkitt lymphoma in adults. Hematology Am Soc Hematol
51. Goldman SC, Holcenberg JS, Finklestein JZ, et al: A randomized comparison between Educ Program 341–348, 2008.
rasburicase and allopurinol in children with lymphoma or leukemia at high risk for 71. Hoelzer D, Ludwig WD, Thiel E, et al: Improved outcome in adult B-cell acute lympho-
tumor lysis. Blood 97:2998–3003, 2001. blastic leukemia. Blood 87:495–508, 1996.

Kaushansky_chapter 102_p1671-1678.indd 1677 17/09/15 3:21 pm